Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04493476
Other study ID # 0206-19COM2
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date October 1, 2020
Est. completion date December 1, 2022

Study information

Verified date July 2020
Source Carmel Medical Center
Contact Yuval Kaufman, Dr
Phone 972-4-9551028
Email mdykaufman@clalit.org.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, double-blind, placebo-controlled trial examining the effect of Chinese herbal medicine combined with curcumin defined as a dietary supplement on a study group of women with endometriosis, compared to control group.

research product:Chinese herbal extract and curcumin extract, which appear as nutritional supplements in the Ministry of Health database, the research product is packed in 800mg capsules.

Intended use: Composition of 14 different nutritional supplements, in Chinese herbal formula, for the treatment of endometriosis and its symptoms. The formula is formulated according to Chinese medicine principles and aims to reduce inflammation of the pelvic organs and reduce the levels of pain caused by endometriosis disease.

Objectives:Examine the Effect of Using Nutritional Supplements on Symptoms in Patients with Targeted Endometriosis Symptoms.

Primary Endpoints:

Benefit of pain in women suffering from symptoms of endometriosis patients taking herbal extract for 4 months of treatment.

Structure of the study:A prospective, double-blind, double-blind, placebo-controlled (randomized) placebo-controlled trial involving women suffering from endometriosis symptoms and meeting the inclusion and exclusion criteria and who agreed to participate in the study. The women will be randomly divided into the following two arms:

1. Study Group - Taking a daily dose of dietary supplement extract capsules

2. Control group - take a daily dose of Invo capsules Treatment efficacy will be measured according to a dedicated patient questionnaire with endometriosis symptoms that assess quality of life measures.

The study population will include 60 symptomatic women treated at the Multidisciplinary Center for Endometriosis Therapy at Lynn Medical Center.


Description:

Endometriosis is a chronic and progressive gynecological disease, with an estimated invention of between 8-10% of women of childbearing age in the Western world . The disease is characterized by the presence of tissue resembling endometrial tissue . The tissue cells that are in the uterine space can settle on different organs in the pelvis. The cells continue to respond to the hormonal cycle as if they were inside the uterus and in each menstrual can grow and bleed. At the same time, an inflammatory process can be associated with various symptoms of pain. Symptoms are not specific but usually cyclical according to menstrual timing and include: severe menstrual cramps, heavy bleeding, diarrhea and constipation, infertility, urinary pain, recurrent infections, fainting, intercourse pain, leg pain and more.

The current practice is based on the removal of endometriosis lesions in surgery and / or drug therapy designed to suppress existing lesion activity and prevent lesion recurrence after surgery. To diagnose endometriosis in a definite way it is necessary to visually identify the lesions and by biopsy in surgery. In many patients, the symptoms of endometriosis can be treated pharmacologically and without surgery . Therefore, it is now widely accepted in many cases to treat pharmacologic anatomy empirically based on an estimated endometriosis-based diagnosis of appropriate anemia, gynecological examination, and vaginal ultrasound.

Very little has been investigated regarding the integration of endometriosis phenomena through complementary medicine that includes herbs and acupuncture, despite the vast clinical knowledge and experience gained. In the present study, we would like to examine the effect of complementary medicine that would include a combination of herbal remedies for pain symptoms in women with endometriosis.

In recent years, the Western world has begun to integrate complementary medicine in various treatments for chronic diseases and in particular endometriosis . The Chinese language review included 13 Chinese randomized clinical trials from 1994 to 2000. The studies included 1076 women who received Chinese herbs alone or in combination with recognized drugs . The proposed mechanism is that the herbs are involved in regulation of the endocrine and immune system and which improve blood flow and anti-inflammatory activity .

The ability of Chinese herbs to affect physiological changes indicates a mechanism of biological action of the herbs. However, the medicinal plants appear to have lower potency activity than synthetic drugs. They can contain an anti-inflammatory but less active ingredient than synthetic steroids.

Research Rationale Endometriosis is a chronic disease of infertile women. The main treatment is based on hormone drug therapy and surgical treatment. There are patients who, despite these treatments, still suffer from symptoms of endometriosis. There are also patients who are medically balanced but have to stop treatment for various reasons and need another non-hormonal response. Herbs have been found effective in treating gynecological problems and especially in chronic pelvic pain. They may relieve the symptoms in those women who wish to avoid hormone or surgical treatment or who are not symptomatically balanced despite the usual treatments.

The purpose of the study Investigate the effectiveness of treatment of symptoms and quality of life measures by the use of medicinal plants in women with symptoms of endometriosis.

Preliminary Results Primary Endpoints Benefit of pain indices in women suffering from symptoms of endometriosis between patients taking herbal extract and patients taking Invo for 4 months of treatment. Benefit is defined as a statistically significant improvement in VAS dimensions that will be examined by a daily journal and medical questionnaire.

Secondary Results Secondary Endpoints Quality-Of-Life Benefit Defined as a statistically significant improvement in questionnaire indices.

Also, a reduction in the use of painkillers and a lack of working days each month between the two groups.

The research product:Chinese herbal extract and curcumin extract, which appear as nutritional supplements in the Ministry of Health database, the research product is packed in 800mg capsules.

Intended use: Composition of 14 different nutritional supplements, in Chinese herbal formula, for the treatment of endometriosis and its symptoms. The formula is formulated according to Chinese medicine principles and aims to reduce inflammation of the pelvic organs and reduce the levels of pain caused by endometriosis disease.

Objectives:Examine the Effect of Using Nutritional Supplements on Symptoms in Patients with Targeted Endometriosis Symptoms.

Primary Endpoints:

Benefit of pain indices in women suffering from symptoms of endometriosis between patients taking herbal extract and patients taking Invo for 4 months of treatment.

Structure of the study:A prospective, double-blind, double-blind, placebo-controlled (randomized) placebo-controlled trial involving women suffering from endometriosis symptoms and meeting the inclusion and exclusion criteria and who agreed to participate in the study. The women will be randomly divided into the following two arms:

1. Study Group - Taking a daily dose of dietary supplement extract capsules

2. Control group - take a daily dose of Invo capsules Treatment efficacy will be measured according to a dedicated patient questionnaire with endometriosis symptoms that assess quality of life measures.

The study population will include 60 symptomatic women treated at the Multidisciplinary Center for Endometriosis Therapy at Lynn Medical Center.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date December 1, 2022
Est. primary completion date May 1, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Women with surgically diagnosed endometriosis and / or a clinical picture suitable for endometriosis.

2. Age 18 to 45. The patient is capable and willing to agree in writing ICF to enter the study.

3. There is no known allergy to any of the ingredients in the plant formula according to a sensitive patient's questioning.

4. The patient agrees to use contraception during the study period until the end of the medication if hormone therapy is not taken.

5. The patient has not changed / stopped / started hormone therapy in the previous three months of recruitment.

Exclusion Criteria:

Treated with kidney or liver disease, severe cardiovascular disease, chronic pancreatitis, diabetes or gallstones.

2. Treated with another cause of pain known. 3. Treated during pregnancy or breastfeeding. 4. A patient who is unable or unwilling to agree in writing for inclusion in the study.

5. Allergy is known to be one of the ingredients in the plant formula. 6. A patient who started hormone therapy, changed hormone therapy, or stopped in the three months prior to recruiting for the study.

7. Women who do not speak the Hebrew language about her ignorance

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chinese herbal formula
Chinese herbal formula

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Carmel Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in visual analogue scale pain scores in women with endometriosis symptoms treated with the herbal extract formula Improvement will be measured by statistically significant visual analogue scale score differences collected by daily patient questionnaires 6 months
Secondary Improvement in quality of life followiing treatment with the herbal extract formula Statistically significant changes in QOL questionnaire scores and decrease in use of analgesics 6 months
See also
  Status Clinical Trial Phase
Completed NCT01931670 - A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain Phase 3
Recruiting NCT05648669 - A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain Phase 3
Completed NCT04081532 - The Effectiveness of Laparoscopic Treatment of Superficial Endometriosis for Managing Chronic Pelvic Pain N/A
Recruiting NCT06101303 - Endometriosis Pain
Completed NCT04665414 - Diagnosis of Adenomyosis Using Ultrasound, Elastography and MRI
Completed NCT03690765 - Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis
Recruiting NCT05153512 - ADOlescent DysmenoRrhea Endometriosis Assessment Magnetic Resonance Imaging (Adodream)
Active, not recruiting NCT04171297 - Ultrasound Evaluation of the Pelvis in Women With Suspected Endometriosis Scheduled for Laparoscopic Surgery
Recruiting NCT04172272 - The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures N/A
Completed NCT04565470 - Strategies of Self-management of Endometriosis Symptoms
Completed NCT03613298 - Treatment by HIFU With Focal One® of Posterior Deep Infiltrating Endometriosis Lesions With Intestinal Involvement. N/A
Withdrawn NCT05568940 - Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
Not yet recruiting NCT03464799 - Does Immunotherapy Have a Role in the Management of Endometriosis?
Active, not recruiting NCT03002870 - Characteristics of Patient Population With Endometriosis N/A
Withdrawn NCT03272360 - Endometriosis Biomarker Discovery Study N/A
Completed NCT02973854 - Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Endometriosis: Identification of Potential Relevant Biomarkers to Diagnose and Treat
Recruiting NCT02481739 - Laparoscopic Surgical Management of Endometriosis on Fertility N/A
Active, not recruiting NCT02754648 - Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve N/A
Completed NCT06106932 - GnRH-a on Angiogenesis of Endometriosis N/A
Completed NCT02387931 - Supplementation in Adolescent Girls With Endometriosis Phase 4